The Optics of Health Care Reform
There are plenty of reasons Wall Street doesn’t like health care reform. The biggest one, though, may be how hard it is to see over a cliff—the patent cliff that is resetting valuations across the Big Pharma sector.
There are plenty of reasons Wall Street doesn’t like health care reform. The biggest one, though, may be how hard it is to see over a cliff—the patent cliff that is resetting valuations across the Big Pharma sector.